Newswise — PLYMOUTH MEETING, PA [May 20, 2020] —The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced six new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program. The honorees will receive up to $150,000 in funding to study ways to improve care and help advance therapy for people with breast, colorectal, pancreatic, prostate, and small cell lung cancer, as well as pediatric acute myeloid leukemia. The NCCN Oncology Research Program (ORP) managed the selection process and will oversee the projects, which will each extend for the next two years.
“NCCN Foundation Young Investigator Award recipients go on to make incredible contributions to the global oncology community,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “These men and women are among the best of the best up-and-coming cancer researchers, and NCCN is proud to provide a step up on their career journey. Each of these studies represents a critical learning opportunity that can help us save lives and lessen hardships for people with cancer.”
The 2020 NCCN Foundation YIA recipients are:
- Agnieszka Czechowicz, MD, PhD, Assistant Professor of Pediatrics, Stanford University School of Medicine
- “Development of anti-hKIT Chimeric Antigen Receptor T-Cells as a Dual Hematopoietic Stem Cell Transplantation (HSCT) Conditioning and Immunotherapeutic Agent for Cure of Pediatric Acute Myeloid Leukemia (AML)”
- Wade T. Iams, MD, Assistant Professor of Medicine, Vanderbilt University Medical Center
- “Quantifying Minimal Residual Disease in Patients with Small Cell Lung Cancer”
- Shivan Mehta, MD, MBA, MSHP, Assistant Professor of Medicine, University of Pennsylvania
- “Choice Architecture and Mailed Colorectal Cancer Screening Outreach in a Community Health Setting”
- Omar Y. Mian, MD, PhD, Assistant Professor and Associate Staff, Case Comprehensive Cancer Center/Cleveland Clinic Taussig Cancer Institute*
- “Modulating Intratumoral Androgen Biosynthesis to Selectively Sensitize Prostate Cancer to Radiotherapy”
- Mustafa Raoof, MD, Assistant Clinical Professor, City of Hope Beckman Research Institute
- “Targeting Transcription-Replication Conflicts in KRAS-driven Pancreatic Cancer”
- Jennifer Y. Sheng, MD, Assistant Professor in Oncology, Johns Hopkins University School of Medicine
- “An Adaptive Nutrition and Exercise Weight loss (A-NEW) Study for Breast Cancer Survivors”
“The NCCN Foundation is proud to honor these talented researchers as they explore the course of treatment innovation and advancement for people with cancer,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. “We look forward to seeing where their research takes them on the path toward future breakthroughs.”
Following precedence, research results from these six recipients will be presented during the NCCN 2022 Annual Conference. Similar presentation from the recipients of the 2018 NCCN Young Investigator Awards were scheduled for the NCCN 2020 Annual Conference, which was postponed due to the Coronavirus Disease 2019 (COVID-19) pandemic. However, posters that were accepted for the conference can now be viewed online at NCCN.org/conference, with abstracts printed in JNCCN—Journal of the National Comprehensive Cancer Network.
The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database. For more information on these and other collaborative cancer research projects, see NCCN.org/orp.
The 2020 NCCN Foundation Young Investigator Awards were made possible through support from AbbVie Inc; Amgen Inc.; AstraZeneca; Genentech, a member of the Roche Group; Incyte Corporation; Pfizer Inc.; Merck & Co., Inc.; and Pharmacyclics, An AbbVie Company. Visit NCCN.org/patients to learn more about the NCCN Foundation or make a donation to support future research and patient resources.
* Updated on August 21, 2020 with the addition of Dr. Mian.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg and Twitter @NCCN.
About the NCCN Foundation
The NCCN Foundation® was founded by the National Comprehensive Cancer Network® (NCCN®) to empower people with cancer and advance oncology innovation. The NCCN Foundation empowers people with cancer and their caregivers by delivering unbiased expert guidance from the world’s leading cancer experts through the library of NCCN Guidelines for Patients® and other patient education resources. The NCCN Foundation is also committed to advancing cancer treatment by funding the nation’s promising young investigators at the forefront of cancer research. For more information about the NCCN Foundation, visit NCCN.org/patients.